Quote · The Diary Of A CEO with Steven Bartlett
Leading Cancer Researcher: They’re Ignoring My Research, Cancer Patients Must Know This!
Where this was said
Using the Keto Diet to Supercharge Chemo
At 1:00:17 · chapter starts 58:35
The most clinically actionable section of the episode, this chapter lays out precisely how Seyfried's metabolic approach transforms standard treatment. Cancer cells are protected in part by the fermentation waste products — lactic acid and succinic acid — they dump into the tumour microenvironment; these metabolites actively block chemotherapy and immunotherapy from working. When a patient is put into nutritional ketosis, glucose supply to the tumour drops, fermentation slows, and this chemical shield is stripped away. [1] — Thomas Seyfried "When cancer patients enter nutritional ketosis before chemotherapy, tumour cells lose their metabolic shield — the lactic acid and succinic…" 58:50 Healthy cells, meanwhile, switch to burning ketones and enter a slower, more protective metabolic state — what Bartlett memorably summarises as 'bunker mode' — making them far more resistant to chemotherapy's toxicity. The result: the same anti-cancer effect with dramatically lower drug doses, fewer side effects, and a preserved microbiome and immune system. Seyfried describes Istanbul clinics achieving 4–5 year survival in patients with terminal pancreatic cancer using this exact combination. He also explains how immunotherapy works better when applied after metabolic therapy has made the tumour indolent and isolated — attacking a weakened foe rather than a raging one. Mainstream oncology's sequencing, he argues, gets this backwards.
When cancer patients enter nutritional ketosis before chemotherapy, tumour cells lose their metabolic shield — the lactic acid and succinic acid waste that normally protects them. The result: far lower doses of chemo achieve much greater effect, while healthy cells are protected by their ability to slow down. Istanbul clinics are already doing this with pancreatic cancer patients surviving 4–5 years.
The press-pulse therapeutic strategy first 'presses' — restricts glucose via ketogenic diet and fasting to starve the tumour and reduce its aggressiveness. Then it 'pulses' — delivers drugs targeting glutamine to kill the now-weakened cancer cells, particularly the metastatic hybrids. Low-dose chemo and immunotherapy then finish off what remains, attacking the tumour at its weakest.
